These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 16899609)
1. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609 [TBL] [Abstract][Full Text] [Related]
2. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417 [TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877 [TBL] [Abstract][Full Text] [Related]
4. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044 [TBL] [Abstract][Full Text] [Related]
5. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399 [TBL] [Abstract][Full Text] [Related]
6. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B; J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359 [TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
9. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Rydén L; Jönsson PE; Chebil G; Dufmats M; Fernö M; Jirström K; Källström AC; Landberg G; Stål O; Thorstenson S; Nordenskjöld B; ; Eur J Cancer; 2005 Jan; 41(2):256-64. PubMed ID: 15661551 [TBL] [Abstract][Full Text] [Related]
10. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595 [TBL] [Abstract][Full Text] [Related]
11. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391 [TBL] [Abstract][Full Text] [Related]
12. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459 [TBL] [Abstract][Full Text] [Related]
13. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479 [TBL] [Abstract][Full Text] [Related]
14. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725 [TBL] [Abstract][Full Text] [Related]
16. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814 [TBL] [Abstract][Full Text] [Related]
17. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF; Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645 [TBL] [Abstract][Full Text] [Related]
18. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
19. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755 [TBL] [Abstract][Full Text] [Related]
20. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Hilsenbeck SG; Osborne CK Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]